5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC)
    Meeting Abstract

    Rosenberg, J. E.; Sridhar, S. S.; Zhang, J.; Smith, D. C.; Ruether, J. D.; Flaig, T. W.; Baranda, J. C.; Lang, J. M.; Plimack, E. R.; Sangha, R. S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study
    Meeting Abstract

    Meric-Bernstam, F.; Lee, R. J.; Carthon, B. C.; Iliopoulos, O.; Mier, J. W.; Patel, M. R.; Tannir, N. M.; Owonikoko, T. K.; Haas, N. B.; Voss, M. H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase Ill trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA
    Meeting Abstract

    Morris, M. J.; De Wit, R.; Vogelzang, N. J.; Tagawa, S. T.; Higano, C. S.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Clinicopathologic and genomic characterization of parenchymal brain metastases (BM) in prostate cancer (PCa)
    Meeting Abstract

    Mota, J. M. S. C.; Teo, M. Y.; Knezevic, A.; Bambury, R. M.; Hatzoglou, V.; Autio, K. A.; Abida, W.; Gopalan, A.; Fine, S.; Danila, D. C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Invasive urothelial cancer (iUC) with FGFR3 hotspot mutation/fusion (FGFR3+): A molecularly and clinically distinctive entity?
    Meeting Abstract

    Mota, J. M. S. C.; Teo, M. Y.; Li, H.; Balar, A. V.; Milowsky, M. I.; Funt, S. A.; Lee, C. H.; Regazzi, A. M.; Berger, M. F.; Solit, D. B.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214
    Meeting Abstract

    McDermott, D. F.; Rini, B. I.; Motzer, R. J.; Tannir, N. M.; Escudier, B.; Kollmannsberger, C. K.; Hammers, H. J.; Porta, C.; George, S.; Donskov, F.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Methylation-associated miR193b silencing activates master drivers of aggressive prostate cancer
    Meeting Abstract

    Mazzu, Y. Z.; Chakraborty, G.; Yoshikawa, Y.; Nandakuma, S.; Armenia, J.; Jehane, L. E.; Lee, G. S. M.; Mucci, L.; Kantoff, P. W.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Genomic biomarkers of response to nivolumab/ipilimumab (nivo/ipi) and nivolumab (nivo) monotherapy in 108 patients with advanced renal cell carcinoma
    Meeting Abstract

    Lee, C. H.; Di Natale, R. G.; Chowell, D.; Makarov, V.; Redzematovic, A.; Murray, S. J.; Carlo, M. I.; Voss, M. H.; Feldman, D. R.; Motzer, R. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Rates of occult brain metastases in patients (pts) with advanced renal cell carcinoma (RCC): A cohort study from patients treated across 22 clinical trials
    Meeting Abstract

    Kotecha, R.; Redzematovic, A.; Motzer, R. J.; Voss, M. H.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Defining "platinum-ineligible" patients with metastatic urothelial cancer (mUC)
    Meeting Abstract

    Gupta, S.; Sonpavde, G.; Grivas, P.; Apolo, A. B.; Plimack, E. R.; Flaig, T. W.; Hahn, N. M.; Balar, A. V.; Bajorin, D. F.; Galsky, M. D.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save